Shimobi Onuoha

USPTO Granted Patents = 31 (Patent Applications = 32)

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 10 (Patent Applications = 41)

Average Co-Inventor Count = 5.4

ph-index = 4

Forward Citations = 63(Granted Patents)

Location History:

Bishop's Stortford, GB (2016 - 2021)
London, GB (2018 - 2024)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2016-2025

Loading Chart...

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12454578 - Cytolytic immune cell comprising BCMA- and CD19-specific chimeric antigen receptors (2025-10-28),

2. 12398194 - Cell lexpressing two chimeric antigen receptors (CARs) at the cell surface (2025-08-26),

3. 12325733 - Binding domain (2025-06-10),

4. 12241124 - Molecular assessment of TRBC usage (2025-03-04),

5. 12241068 - CD79-specific chimeric antigen receptor (2025-03-04),

6. 12234295 - Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof (2025-02-25),

7. 12187769 - Cell (2025-01-07),

8. 12049510 - Chimeric antigen receptor (2024-07-30),

9. 11963981 - Chimeric antigen receptor (2024-04-23),

10. 11945867 - T-cell receptor constant region 1 antibody or T-cell receptor constant region 2 antibody (2024-04-02),

11. 11701386 - Cell (2023-07-18),

12. 11648274 - Polypeptide (2023-05-16),

13. 11590170 - Chimeric antigen receptor (2023-02-28),

14. 11479614 - Methods for treating cancer or modulating T cells or NK cells in a subject with cancer by administering cells comprising chimeric cytokine receptors (2022-10-25),

15. 11479613 - Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteins (2022-10-25),

Title: **Innovations and Achievements of Shimobi Onuoha**

Introduction

Shimobi Onuoha, an accomplished inventor based in London, GB, holds an impressive portfolio of 23 patents. His work primarily focuses on advancements in medical technology, particularly in the field of immunotherapy and genetic assessment.

Latest Patents

Among his latest contributions to the field, Onuoha has developed a patent entitled "Molecular Assessment of TRBC Usage." This invention describes a method for determining the T cell receptor β chain (TRBC) gene type of a cell by assessing the J gene type expressed in that cell, ultimately leading to a more accurate inference of the TRBC gene type. Additionally, it encompasses the use of CAR T cells targeted to specific TRBC types, which greatly enhances medical treatment modalities. Another significant patent is the "CD79-specific Chimeric Antigen Receptor," which involves a chimeric antigen receptor (CAR) that binds specifically to CD79. This invention also includes the relevant nucleic acid sequence and vector encoding the CAR, along with cells that express this CAR on their surface.

Career Highlights

Onuoha has had a notable career, during which he contributed to leading companies in the biotech sector. His experience includes working at Autolus Limited and UCL Business Plc, where he played a vital role in advancing innovative treatments and therapies based on his patented technologies.

Collaborations

Throughout his career, Onuoha has teamed up with several distinguished colleagues, including Shaun Cordoba and Simon Thomas. These collaborations have enabled him to foster an environment of innovation, sharing insights and expertise to further enhance the field of biomedicine.

Conclusion

Shimobi Onuoha's contributions to the fields of immunotherapy and genetic assessment have significantly impacted medical advancements. His numerous patents reflect his commitment to innovation and dedication to improving healthcare solutions. As he continues his work, the potential for new discoveries remains promising, laying the groundwork for future breakthroughs in medical technology.

This text is generated by artificial intelligence and may not be accurate.